Kerala Kaumudi Online
Thursday, 25 February 2021 1.25 AM IST

Bharat Biotech to pay compensation if Covaxin causes side effects; recipients should sign consent form


NEW DELHI: Bharat Biotech, which has received a government purchase order for the supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, will pay compensation to recipients in case of any 'serious adverse' effects experienced after receiving the antidote.

A consent form to be signed by the vaccine recipients said, ''In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres and hospitals.'' ''The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,'' the form said.

In phase 1 and 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes againstCOVID-19.

However, the clinical efficacy of the vaccine is yet to be established and it is still being studied in phase 3 clinical trials.

''Hence, it is important to appreciate that receiving the vaccine does not mean that other precautions related toCOVID-19 need not be followed,'' it added.

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects caused by the vaccine administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Joint Managing Director of Bharat BiotechInternational Ltd, Suchitra Ella in her Twitter account said,'' Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.'' Covaxin is a highly purified and inactivated two-doseSARS-CoV-2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than300 million doses, the drugmaker had said.

Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

The inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) biocontainment facility, one of its kind in the world.

Lorem ipsum dolor sit amet
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
We respect your privacy. Your information is safe and will never be shared.